FAQ Directory

Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can  ask a question through My NCQA.

Filter Results
  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.

You are viewing a single FAQ from your previous search. Clear Search

expand all

1.27.2016 P4P NDC Tables We noticed discrepancies between pharmacy tables in the MY 2015 Value Based P4P Manual and the drugs included in the HEDIS 2016 Volume 2 pharmacy tables and HEDIS 2016 NDC lists. Is this intentional?

The pharmacy tables included in the MY 2015 Value Based P4P Manual should align with the pharmacy tables in HEDIS 2016 Volume 2.
 
General Guideline 32. Measures That Use Pharmacy Data states, “NCQA specifies a standardized list of medications known as the Nation Drug Code (NDC) list that applies to each pharmacy dependent measure. POs and health plans are required to use the list for applicable measures.” Find the NDC lists at: http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2016/HEDIS2016NDCLicense/HEDIS2016FinalNDCLists.aspx
 
The table contains changes that should be reflected in the P4P drug tables.   
 

P4P Table NameDrug Table Corrections
CDC-A, CBPH-A, and SPD-A: Prescriptions to Identify Members with Diabetes
 
 
  • Add “Empaglifozin-linagliptin” to the Antidiabetic combinations row.
  • Add “Empagliflozin-metformin” to the Antidiabetic combinations row.
  • Add “Dulaglutide” to the GLP1 agonists row.
  • Add “Insulin human inhaled” to the Insulin row.
  • Add “Canagliflozin-metformin” to the Antidiabetic combinations row.
  • Add “Empagliflozin” to the Sodium glucose cotransporter 2 (SGLT2) inhibitor row.
Table SPC-B: High and Moderate-Intensity Statin Medications
  • Remove obsolete medication “Aspirin-pravastatin 40-80mg” from the Moderate-intensity statin therapy row.
Table SPD-B: High, Moderate and Low-Intensity Statin Prescriptions
  • Remove obsolete medication “Aspirin-pravastatin 40-80mg” from the Moderate-intensity statin therapy row.
  • Remove obsolete medication “Aspirin-pravastatin 20mg” from the Low-intensity statin therapy row.
Table OMW-A: Osteoporosis Therapies
  • Remove obsolete medication “Calcium carbonate-risedronate” from the Biophosphonates row.
Table CHL-A: Prescriptions to Identify Contraceptives
  • Remove obsolete medication “Estradiol-medroxyprogesterone” from the Contraceptives row.
Table AMR-B: Asthma Controller and Reliever Medications
  • Remove obsolete medication “Triamcinolone” from the Inhaled corticosteroids row.
Table  CWP-A and URI-A: Antibiotic Medications
  • Remove obsolete medication “Sulfisoxazole” from the Sulfonamides row.

ALL 2015